Heptares in up to $200 million deal with Novartis for StaR technology for drug leads against a GPCR target

13 October 2009

UK-based Heptares Therapeutics, a drug discovery company focused on G-protein-coupled receptor (GPCR) targets, has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Swiss drug major Novartis. The agreement includes upfront and potential milestone payments to Heptares totaling up to $200 million plus royalties. Further financial terms were not disclosed.

StaR technology enables GPCRs, normally membrane-bound, to be worked on in solution, allowing the use of structure-based drug discovery technologies and the discovery of novel drugs addressing this important set of targets. Heptares is deploying this technology principally to generate small molecule drugs against currently difficult or intractable GPCR targets in several disease areas.

'This is an excellent early deal for Heptares, endorsing our StaR technology and further strengthening our financial position,' said chief executive Malcolm Weir. 'The deal with the Novartis Option Fund demonstrates confidence that our approach can unlock the potential of GCPR targets and forms a solid foundation for other partnerships with leading pharmaceutical companies.'

'The potential of GPCRs as targets for drug discovery is well recognized, but it has always been a challenge to gain structural information on GPCRs,' said Anja Koenig for the Novartis Option Fund. 'We believe that the power of Heptares' technology to resolve GPCR structures and their expertise in small-molecule chemistry will lead to rapid progress in the drug discovery program against Novartis' nominated target.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical